Donald Bellgrau
Fondatore presso ApopLogic Pharmaceuticals, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Richard Duke | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO.
The University of Colorado
| - |
George Hank Brown | M | 84 |
The University of Colorado
| 19 anni |
Lajos Gera | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 anni |
Renae Cormier | F | 52 |
The University of Colorado
| 1 anni |
John M. Stewart | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 anni |
Daniel D. Chan | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 anni |
Paul Bunn | M | 79 |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 anni |
Jeff Saywitz | M | - |
The University of Colorado
| - |
Richard Lee Lewis | M | - |
The University of Colorado
| - |
Sandy Hicks | F | - |
The University of Colorado
| - |
Alan Weimer | M | - |
The University of Colorado
| - |
Alan Greenberg | M | - |
The University of Colorado
| - |
Marcelo R. Bergquist | M | - |
The University of Colorado
| - |
Michael C. Mozer | M | - |
The University of Colorado
| - |
Benjamin C. Schnell | M | - |
The University of Colorado
| - |
Heidi A. Ganahl | F | - |
The University of Colorado
| - |
Heather Haugen | M | - |
The University of Colorado
| - |
Edward J. Weiler | M | - |
The University of Colorado
| - |
Sharon Bakke | F | - |
The University of Colorado
| - |
Chan H. Pollock | M | - |
The University of Colorado
| - |
George A. Sissel | M | 87 |
The University of Colorado
| - |
Kristi S. Anseth | M | - |
The University of Colorado
| - |
Patricia Nelson Limerick | F | - |
The University of Colorado
| - |
Stephen R. Daniels | M | - |
The University of Colorado
| - |
Lauren Shaner | F | - |
The University of Colorado
| - |
Lynda Gibbons | F | - |
The University of Colorado
| - |
Alexander Bracken | M | - |
The University of Colorado
| - |
John W. Birks | M | - |
The University of Colorado
| - |
Mary S. Randall | F | - |
The University of Colorado
| - |
Jaime Modiano | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 anni |
Michael S. Anger | M | - |
The University of Colorado
| - |
Robin Shandas | M | - |
The University of Colorado
| - |
Peter Mariner | M | - |
The University of Colorado
| - |
Mark A. Wickert | M | - |
The University of Colorado
| - |
David R. Laube | M | - |
The University of Colorado
| - |
Leslie Leinwand | M | - |
The University of Colorado
| - |
Chris Bowman | M | - |
The University of Colorado
| - |
V. Michael Holers | M | - |
The University of Colorado
| - |
Raul Guisado | M | - |
The University of Colorado
| - |
John F. Carpenter | M | - |
The University of Colorado
| - |
Betty R. Jackson | M | - |
The University of Colorado
| - |
John R. Woodhull | M | 90 |
The University of Colorado
| - |
Garret Moddel | M | - |
The University of Colorado
| - |
Robert B. Uhler | M | - |
The University of Colorado
| - |
Craig W. Donaldson | M | - |
The University of Colorado
| - |
Thomas Robert Cech | M | 76 |
The University of Colorado
| 34 anni |
William H. Weintraub | M | 81 |
The University of Colorado
| - |
Marvin H. Caruthers | M | 84 |
The University of Colorado
| 45 anni |
Errol L. Biggs | M | 83 |
The University of Colorado
| - |
John P. Raeder | M | - |
The University of Colorado
| - |
Richard Abrams | M | - |
The University of Colorado
| - |
Michael D. Iseman | M | 85 |
The University of Colorado
| 44 anni |
Joe M. McCord | M | 79 |
The University of Colorado
| - |
David L. Braddock | M | 79 |
The University of Colorado
| 23 anni |
George P. Sape | M | 79 |
The University of Colorado
| - |
James Rothe | M | 80 |
The University of Colorado
| 38 anni |
Dale N. Hatfield | M | 86 |
The University of Colorado
| 23 anni |
Misha Plam | M | - |
The University of Colorado
| - |
Richard D. Krugman | M | - |
The University of Colorado
| - |
Ryan T. Gill | M | - |
The University of Colorado
| 23 anni |
Michael B. Guthrie | M | - |
The University of Colorado
| - |
Robert H. Keeley | M | 83 |
The University of Colorado
| 32 anni |
James A. Lemons | M | - |
The University of Colorado
| - |
Wayne F. Cascio | M | - |
The University of Colorado
| - |
James Ehrlich | M | - |
The University of Colorado
| - |
Tom Gadek | M | - |
The University of Colorado
| - |
David Grooms | M | - |
The University of Colorado
| - |
Christopher Staszak | M | - |
The University of Colorado
| - |
Betty Arkell | F | - |
The University of Colorado
| - |
Christopher Ozeroff | M | 65 |
The University of Colorado
| - |
William Barker | M | 75 |
The University of Colorado
| 16 anni |
Melissa Gonzales | F | - |
The University of Colorado
| - |
Paul Terrence O'Rourke | M | - |
The University of Colorado
| - |
Ryan A. Martens | M | 58 |
The University of Colorado
| - |
David Secunda | M | - |
The University of Colorado
| - |
Larry Gold | M | 82 |
The University of Colorado
| 54 anni |
Janet Pritchard | F | - |
The University of Colorado
| - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 77 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Donald Bellgrau
- Contatti personali